RE: Efficacy and safety of personalized optimal programmed cell death 1 ligand combinations in advanced non-small cell lung cancer: a network meta-analysis.

IF 9.9 1区医学 Q1 ONCOLOGY

JNCI Journal of the National Cancer Institute Pub Date : 2025-06-06 DOI:10.1093/jnci/djaf132

Junmei Zhang, Shuai Wang, Tingting Li, Xuefei Liu

引用次数: 0

查看原文本刊更多论文

个性化最佳程序性细胞死亡1配体组合治疗晚期非小细胞肺癌的疗效和安全性：一项网络荟萃分析。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

JNCI Journal of the National Cancer Institute 医学-肿瘤学

CiteScore

17.00

自引率

2.90%

发文量

203

审稿时长

4-8 weeks

期刊介绍： The Journal of the National Cancer Institute is a reputable publication that undergoes a peer-review process. It is available in both print (ISSN: 0027-8874) and online (ISSN: 1460-2105) formats, with 12 issues released annually. The journal's primary aim is to disseminate innovative and important discoveries in the field of cancer research, with specific emphasis on clinical, epidemiologic, behavioral, and health outcomes studies. Authors are encouraged to submit reviews, minireviews, and commentaries. The journal ensures that submitted manuscripts undergo a rigorous and expedited review to publish scientifically and medically significant findings in a timely manner.